Scarica l'app Stockscreener
36.80
2.05%
-0.77
Dopo l'orario di chiusura:
37.05
0.25
+0.68%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HIMS Giù?
Forum
Previsione
Precedente Chiudi:
$37.57
Aprire:
$37.635
Volume 24 ore:
16.22M
Relative Volume:
0.65
Capitalizzazione di mercato:
$8.52B
Reddito:
$2.35B
Utile/perdita netta:
$128.37M
Rapporto P/E:
70.48
EPS:
0.5221
Flusso di cassa netto:
$57.42M
1 W Prestazione:
+12.50%
1M Prestazione:
+33.77%
6M Prestazione:
+10.15%
1 anno Prestazione:
-22.46%
Intervallo 1D:
$36.03
$37.99
Intervallo di 1 settimana:
$31.59
$38.50
Portata 52W:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Nome
Hims Hers Health Inc
Settore
Telefono
415-851-0195
Indirizzo
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
36.80 | 8.02B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
16.77 | 50.65B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.82 | 41.09B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.64 | 39.45B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
74.80 | 30.13B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
555.91 | 23.00B | 3.17B | 1.29B | 1.01B | 27.09 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-24 | Iniziato | JP Morgan | Overweight |
| 2026-03-10 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2026-03-10 | Aggiornamento | Citigroup | Sell → Neutral |
| 2026-03-09 | Aggiornamento | Needham | Hold → Buy |
| 2026-02-24 | Downgrade | BTIG Research | Buy → Neutral |
| 2026-01-12 | Iniziato | Evercore ISI | In-line |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-10-21 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Downgrade | Needham | Buy → Hold |
| 2025-06-04 | Reiterato | Needham | Buy |
| 2025-04-29 | Downgrade | TD Cowen | Buy → Hold |
| 2025-02-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Downgrade | Citigroup | Neutral → Sell |
| 2025-01-07 | Iniziato | BTIG Research | Buy |
| 2024-12-17 | Iniziato | Morgan Stanley | Overweight |
| 2024-11-14 | Downgrade | BofA Securities | Buy → Underperform |
| 2024-08-22 | Iniziato | Needham | Buy |
| 2024-08-09 | Downgrade | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Downgrade | Citigroup | Buy → Neutral |
| 2024-04-16 | Downgrade | Jefferies | Buy → Hold |
| 2024-04-10 | Iniziato | Canaccord Genuity | Buy |
| 2024-02-28 | Aggiornamento | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Iniziato | Leerink Partners | Market Perform |
| 2023-12-07 | Iniziato | Imperial Capital | In-line |
| 2023-07-28 | Iniziato | TD Cowen | Outperform |
| 2023-04-11 | Iniziato | Robert W. Baird | Neutral |
| 2023-02-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-11-08 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Iniziato | Truist | Hold |
| 2022-07-15 | Iniziato | SVB Leerink | Underperform |
| 2022-04-14 | Iniziato | Guggenheim | Buy |
| 2022-04-01 | Ripresa | Credit Suisse | Outperform |
| 2022-03-10 | Iniziato | Deutsche Bank | Hold |
| 2021-12-02 | Iniziato | Jefferies | Hold |
| 2021-11-11 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Iniziato | BofA Securities | Neutral |
| 2021-05-20 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Iniziato | Truist | Hold |
| 2021-03-09 | Iniziato | Credit Suisse | Neutral |
| 2021-03-02 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-02-17 | Iniziato | Citigroup | Neutral |
| 2021-02-12 | Iniziato | Piper Sandler | Neutral |
| 2021-02-08 | Iniziato | Tigress Financial | Buy |
Mostra tutto
Hims Hers Health Inc Borsa (HIMS) Ultime notizie
HIMS Stock Jumps 8% as JPMorgan Facility and Analyst Upgrades Fuel Rally - FXLeaders
HIMS Stock Hits 2026 High After Unlocking $400M Working Capital Through JPMorgan — Retail Gets Less Bearish - Stocktwits
Hims & Hers Health Enters Receivables Purchase Agreement with JPMorgan Chase Bank – Key Terms and Details - Minichart
Hims & Hers Establishes New $400 Million Receivables Facility - TipRanks
Hims & Hers Launches $400 Million Receivables Facility, Amends Revolver to Support Program - TradingView
Hims & Hers (HIMS) adds $400M receivables facility and amends credit deal - Stock Titan
HIMS Stock Surges as Canaccord Genuity Raises Price Target - GuruFocus
Hims & Hers Stock Surges as Analysts Lift Price TargetsHims & Hers Health (NYSE:HIMS) - Benzinga
Hims & Hers stock jumps as Canaccord lifts target ahead of FDA review - TradingView
Hims & Hers Health (NYSE:HIMS) run trims Canaccord upside after GLP-1 reset - TechStock²
BofA raises Hims and Hers stock price target on FDA peptide review - Investing.com
Hims stock gains as FDA revives AdComs (HIMS:NYSE) - Seeking Alpha
HIMS Maintains by B of A Securities -- Price Target Raised to $3 - GuruFocus
HIMS Maintained by Canaccord Genuity -- Price Target Raised to $40 - GuruFocus
Why is Hims & Hers Health stock rallying today? By Investing.com - Investing.com Canada
Hims & Hers stock rises after Canaccord price target hike - Investing.com
Hims & Hers Health, Inc. Stock 12‑Month Price Target Raised to $29.27, Implies 16% Downside - TradingView
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Canaccord raises Hims and Hers stock price target on weight loss drugs - Investing.com Canada
HIMS Stock Slips Overnight After FDA Staff Questions Safety Of Popular Peptides — But One Analyst Says ‘This Isn’t The End’ - Stocktwits
Hims & Hers Health Inc (HIMS) Shares Surge 3.8% -- What GF Score of 81 Tells Investors - GuruFocus
Hims & Hers Health, Inc. (HIMS) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
HIMS Stock On The Mend? New Testosterone Push Builds As GLP-1 Gold Rush Gets Crowded - Stocktwits
Lost Money on Hims & Hers Health, Inc. (HIMS)? Join Class Action Before August 25, 2025Contact Levi & Korsinsky - The National Law Review
Join Class Action to Recover Losses from Hims & Hers Health, Inc - The National Law Review
Class Action Lawsuit Alert: Levi & Korsinsky Reminds Hims & Hers - The National Law Review
Hims & Hers Health Stock (HIMS) Opinions on Business Reacceleration and Analyst Upgrades - Quiver Quantitative
Class Action Filed Against Hims & Hers Health, Inc. (HIMS) Over Securities ViolationsContact Levi & Korsinsky Today - The National Law Review
Trading the Move, Not the Narrative: (HIMS) Edition - Stock Traders Daily
HIMS Stock Eyes Big Monthly Win: Novo Nordisk Calls Hims & Hers One Of Its Most ‘Voluminous’ Telehealth Partners - Stocktwits
OMCL or HIMS: Which Is the Better Value Stock Right Now? - Yahoo! Finance Canada
Hims & Hers Soars After Novo Nordisk Weight-Loss Nod - TipRanks
Hims & Hers: Can Fundamentals Really Support This Rebound Rally? (Downgrade) (NYSE:HIMS) - Seeking Alpha
Why is Hims & Hers Health stock up today? - Traders Union
Key facts: Hims sells GLP‑1s; 2.6M subs; Barclays $39, Leerink $25 - TradingView
Investor relations - HIMS Investor Relations
HIMS Stock | Hims & Hers Health, Inc. Price, Quote, News & Analysis - TipRanks
HIMS News | HIMS & HERS HEALTH INC (NYSE:HIMS) - ChartMill
Hims & Hers Health slips as investors continue to weigh margin pressure and recent financing - Quiver Quantitative
Hims’ obesity drug business may get boost as employers drop coverage - WTVB
Analysis-Hims’ obesity drug business may get boost as employers drop coverage - WHTC
$Hims & Hers Health (HIMS.US)$ - Moomoo
Barclays Raises Price Target On Hims & Hers Health (NYSE: HIMS) As Weight Loss Business Drives Momentum - foreignpolicyjournal.com
Hims & Hers Health Options Spot-On: On June 24th, 62,597 Contracts Were Traded, With 937.02K Open Interest - Moomoo
CVS expands direct-to-consumer GLP-1 weight-loss program - The Business Journals
Is Hims & Hers Health, Inc. (HIMS) a Top Weight Loss Stock After Barclays’ Target Increase? - Insider Monkey
Form 4 Hims Hers Health Inc For: 23 June By Investing.com - Investing.com Nigeria
Hims & Hers CMO Patrick Carroll sells $830,410 in stock By Investing.com - Investing.com Canada
Hims & Hers CFO Oluyemi Okupe sells $619,216 in shares By Investing.com - Investing.com Canada
Hims & Hers (NYSE: HIMS) CMO sells 23,726 shares, retains 181,861 - Stock Titan
[Form 4] Hims & Hers Health, Inc. Insider Trading Activity - Stock Titan
Hims Hers Health Inc Azioni (HIMS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Hims Hers Health Inc Azioni (HIMS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Okupe Oluyemi | Chief Financial Officer |
Jun 22 '26 |
Option Exercise |
5.01 |
6,376 |
31,944 |
302,518 |
| Okupe Oluyemi | Chief Financial Officer |
Jun 22 '26 |
Sale |
34.03 |
18,197 |
619,217 |
284,321 |
5.53%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):